Satoshi Suzuki

Urayasu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Critical cardiovascular complications during non-immunosuppressive therapy for VEXAS syndrome.

Critical cardiovascular complications during non-immunosuppressive therapy for VEXAS syndrome.

Journal: Rheumatology advances in practice

Published: March 03, 2025

SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state.

SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state.

Journal: Rheumatology (Oxford, England)

Published: February 28, 2025

Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy.

Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy.

Journal: Immunological medicine

Published: December 27, 2024

Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.

Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.

Journal: Clinical rheumatology

Published: January 18, 2024

Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review.

Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review.

Journal: Modern rheumatology case reports

Published: February 09, 2021

Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis.

Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis.

Journal: Rheumatology advances in practice

Published: September 19, 2020

Metformin repositioning in rheumatoid arthritis.

Metformin repositioning in rheumatoid arthritis.

Journal: Clinical and experimental rheumatology

Published: April 13, 2020

JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.

JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.

Journal: BMC immunology

Published: May 09, 2017

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.

Journal: Clinical rheumatology

Published: October 15, 2016

Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis.

Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis.

Journal: Autoimmunity

Published: November 21, 2015

Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis - Relationship between disease activity of rheumatoid arthritis and anemia.

Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis - Relationship between disease activity of rheumatoid arthritis and anemia.

Journal: Revista brasileira de reumatologia

Published: June 16, 2015

Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis.

Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis.

Journal: Autoimmunity

Published: October 30, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026